L Robson

1.3k total citations
22 papers, 889 citations indexed

About

L Robson is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, L Robson has authored 22 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in L Robson's work include Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). L Robson is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). L Robson collaborates with scholars based in United Kingdom, South Africa and Italy. L Robson's co-authors include Alan V. Boddy, David R. Newell, Mark R. Middleton, Ruth Plummer, Christopher J. Jones, Jeffrey Evans, Heidi Steinfeldt, Anna L Olsen, Hilary Calvert and Richard H. Wilson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

L Robson

21 papers receiving 859 citations

Peers

L Robson

ONCOL

BIOMA

PRM

Marilynn Vetzel United States

Anthony Cheung United Kingdom

Vessela Vassileva United Kingdom

Mariana Scaranti Brazil

Le-Cun Xu United States

Elena Roşca Romania

Md Zahidul Islam Pranjol United Kingdom

E. Ruth Plummer United Kingdom

Seock Ah Im South Korea

Marilynn Vetzel United States

L Robson

540 ×1.1

483 ×1.0

ONCOL

222 ×1.8

BIOMA

109 ×1.3

PRM

149 ×2.0

Citations per year, relative to L Robson L Robson (= 1×) peers Marilynn Vetzel

Countries citing papers authored by L Robson

Since Specialization

Citations

This map shows the geographic impact of L Robson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Robson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Robson more than expected).

Fields of papers citing papers by L Robson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Robson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Robson. The network helps show where L Robson may publish in the future.

Co-authorship network of co-authors of L Robson

This figure shows the co-authorship network connecting the top 25 collaborators of L Robson. A scholar is included among the top collaborators of L Robson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Robson. L Robson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robson, L, I.E.J. Barnhoorn, & G.M. Wagenaar. (2017). The potential effects of efavirenz on Oreochromis mossambicus after acute exposure. Environmental Toxicology and Pharmacology. 56. 225–232. 42 indexed citations

Danson, Sarah, Peter Johnson, Tim Ward, et al.. (2011). Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Annals of Oncology. 22(7). 1653–1660. 26 indexed citations

Dean, Emma, Duncan I. Jodrell, Sarah Danson, et al.. (2009). Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer. Journal of Clinical Oncology. 27(10). 1660–1666. 66 indexed citations

Plummer, Ruth, Christopher J. Jones, Mark R. Middleton, et al.. (2008). Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(23). 7917–7923. 298 indexed citations

Tolner, Berend, et al.. (2007). A novel human enzyme with a bis-chloro-phenol prodrug for Antibody Directed Enzyme Prodrug Therapy (ADEPT). UCL Discovery (University College London). 2 indexed citations

Ranson, Malcolm, Emma Dean, Tim Ward, et al.. (2007). Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.. Molecular Cancer Therapeutics. 6.

Tolner, Berend, Lucy Smith, Paul Beckett, et al.. (2007). From laboratory to Phase I/II cancer trials with recombinant biotherapeutics. European Journal of Cancer. 43(17). 2515–2522. 10 indexed citations

LaCasse, Eric C., Stephen Morris, Tim Ward, et al.. (2006). AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients. Cancer Research. 66. 1142–1142. 3 indexed citations

Ranson, Malcolm, Caroline Dive, Tim Ward, et al.. (2006). A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors. Journal of Clinical Oncology. 24(18_suppl). 3059–3059. 18 indexed citations

10.

Plummer, E. Ruth, Mark R. Middleton, R. Wilson, et al.. (2005). Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide. Clinical Cancer Research. 11. 6 indexed citations

11.

Boddy, Alan V., E. Ruth Plummer, Julieann Sludden, et al.. (2005). A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules. Clinical Cancer Research. 11(21). 7834–7840. 84 indexed citations

12.

Plummer, Ruth, Mark R. Middleton, R. Wilson, et al.. (2005). First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3065–3065. 37 indexed citations

13.

Bissett, D., J Cassidy, Johann S. de Bono, et al.. (2004). Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). British Journal of Cancer. 91(1). 50–55. 92 indexed citations

14.

Blackhall, Fiona, P. Vasey, M Soukop, et al.. (2003). A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. British Journal of Cancer. 89(7). 1152–1154. 33 indexed citations

15.

Boddy, Alan V., Rachel Todd, J Sludden, et al.. (2003). Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors. 6 indexed citations

16.

Clive, Sally, et al.. (2001). Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist.. PubMed. 7(10). 3071–8. 17 indexed citations

17.

Siddiqui, Neelam, et al.. (1997). A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. British Journal of Cancer. 75(2). 287–294. 37 indexed citations

18.

Wedge, Stephen R., N P Bailey, Alison Humphreys, et al.. (1996). A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Investigational New Drugs. 14(3). 325–335. 45 indexed citations

19.

Ghazal‐Aswad, Saad, M.J. Millward, N P Bailey, et al.. (1996). Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.. Journal of Clinical Oncology. 14(3). 800–805. 11 indexed citations

20.

Bailey, N P, et al.. (1995). 931 Oral folic acid improves lometrexol toxicity profile: A phase I study. European Journal of Cancer. 31. S193–S194. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact